(Q34390281)

1 August 2017

1 reference

title

Nucleoside analogues in the treatment of haematological malignancies (English)

1 reference

1 August 2017

S A Johnson

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Expert Opinion on Pharmacotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

2

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

929-943

1 reference

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Determination of 2-chloro-2'-deoxyadenosine in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

The cytosine arabinoside (Ara-C) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Cerebellar toxicity with high-dose cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Clinical pharmacology of encapsulated sustained-release cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Advanced breast cancer: a phase II trial with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Pharmacoeconomic considerations in treating patients with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.929

21 January 2018

Identifiers

DOI

10.1517/14656566.2.6.929

1 reference

1 August 2017

1 reference